Type 2 diabetes mellitus (T2DM) is associated with multiple underlying pathophysiologic defects which can not be maintained by monotherapy alone. Generally, a combination of glucose-lowering agents having complementary mechanisms of action and no increased risk of hypoglycemia, cardiovascular events, or weight gain can be used at all stages of the T2DM to overcome the treatment failure of monotherapy. Besides, the combination therapy should also provide conveniences for patients such as oral dosing, single-pill formulations, and once-daily administration.
Sodium-glucose cotransporter-2 (SGLT-2) and dipeptidyl peptidase-4 (DPP-4) inhibitors have been proved to meet the above criteria and also improved patient adherence.1 In this regard, Boehringer Ingelheim India and Docplexus have organized a Multi-Specialty Panel Discussion on 13th October 2020 from 07:00 PM IST onwards. In this…
